drugset / Trial / NCT00944541

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

NCT00944541

Non-randomizedCrossoverOpen-labelTreatment

Summary

This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV\< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration (CD4\<350 cells/mL and CD4 earning \<100 cells/mL during last 24 months). The study will include 60 patients whose follow up is carried out for 48 weeks. recruitment period will be maintained for 12 months.

Timeline

Start
2009-09
Primary completion
2010-08
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg
Subject Maraviroc Other / unclassified 300 mg
Subject Maraviroc Other / unclassified 600 mg